1. Home
  2. GFL vs GMAB Comparison

GFL vs GMAB Comparison

Compare GFL & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GFL Environmental Inc. Subordinate voting shares no par value

GFL

GFL Environmental Inc. Subordinate voting shares no par value

HOLD

Current Price

$39.43

Market Cap

16.0B

Sector

N/A

ML Signal

HOLD

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$27.94

Market Cap

16.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GFL
GMAB
Founded
2007
1999
Country
United States
Denmark
Employees
N/A
3029
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.0B
16.9B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
GFL
GMAB
Price
$39.43
$27.94
Analyst Decision
Buy
Strong Buy
Analyst Count
10
8
Target Price
$55.22
$39.81
AVG Volume (30 Days)
2.6M
1.5M
Earning Date
04-29-2026
05-07-2026
Dividend Yield
0.16%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$8.18
$17.85
Revenue Next Year
$7.20
$16.04
P/E Ratio
$5.95
$1.90
Revenue Growth
N/A
N/A
52 Week Low
$36.96
$18.89
52 Week High
$52.00
$35.43

Technical Indicators

Market Signals
Indicator
GFL
GMAB
Relative Strength Index (RSI) 38.79 50.65
Support Level $38.60 $24.95
Resistance Level $45.68 $29.86
Average True Range (ATR) 1.51 0.60
MACD -0.38 0.18
Stochastic Oscillator 28.89 54.42

Price Performance

Historical Comparison
GFL
GMAB

About GFL GFL Environmental Inc. Subordinate voting shares no par value

GFL Environmental Inc is an environmental services company. Its offerings include non-hazardous solid waste management, infrastructure, soil remediation, and liquid waste management services. Its solid waste management business line, which generates the majority of the revenue, consists of the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste. Its Environmental Services business line includes liquid waste and soil remediation. The company's geographical segments are Canada and the United States. The company derives the majority of its revenue from the United States.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: